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 A porcine model of heart failure was
induced by myocardial infarction followed
by rapid ventricular pacing for 4 weeks.
 Catheter-based renal denervation was
performed using an expandable basket
with 4 electrodes to deliver
radiofrequency energy. Histological
examination showed signiﬁcant
denervation of the renal arteries after the
procedure.
 Compared with the control group, animals
that received renal denervation showed
signiﬁcant improvement of cardiac
function as determined by LV ejection
fraction, maximum rate of LV pressure
rise normalized to instantaneous
developed pressure, and reduction of
myocardial and renal norepinephrine
gradient at 10 weeks after procedure.of Hong Kong, Hong Kong, China;
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271SUMMARY
AB BAND ACRONYM S
ACE = angiotensin-converting
enzyme
BNP = B-type natriuretic
peptide
dP/dtmax = the maximum rate
of left ventricular pressure rise
HF = heart failure
IP = instantaneous developed
pressure




MaRenal denervation (RD) is a potential novel nonpharmacological therapy for heart failure (HF). We performed
bilateral catheter-based RD in 10 adult pigs and compared them with 10 control subjects after induction of
HF to investigate the long-term beneﬁcial effects of RD on left ventricular (LV) function and regional norepi-
nephrine gradient after conventional HF pharmacological therapy. Compared with control subjects, animals
treated with RD demonstrated an improvement in LV function and reduction of norepinephrine gradients over
the myocardium and kidney at 10-week follow-up. Our results demonstrated that effective bilateral RD
decrease regional norepinephrine gradients and improve LV contractile function compared with medical therapy
alone. (J Am Coll Cardiol Basic Trans Science 2017;2:270–81) © 2017 The Authors. Published by Elsevier on




RD =TH = tyrosine hydroxylaseH eart failure (HF) is a major medical problemwith substantial health care burden, andthe associated mortality and morbidity of
HF remain high despite advances in pharmacological
and device management (1,2). There is thus a compel-
ling need for new therapies that target the underlying
pathophysiology of HF and further improve clinical
outcome. In patients with HF, increased activity of
the sympathetic nervous system is associated with
progression of left ventricular (LV) dysfunction and
increased mortality (3,4). Both renal afferent and
efferent sympathetic nerves have been proposed to
contribute to the sympathoexcitation in HF (5,6). In
HF, increased central sympathetic neural outﬂow is
associated with cardiac and renal efferent sympa-
thetic nerve activations, and thus, cardiac and renal
norepinephrine spillover (7–9). However, activation
of renal afferent sympathetic nerves caused by renal
hypoxemia and ischemia may also directly induce
increased central sympathetic outﬂow (9,10). Recent
development of catheter-based renal nerve ablation
for treatment of refractory hypertension has led to a
growing interest in renal denervation (RD) for treat-
ment of HF (6,11–16).SEE PAGE 282Prior studies showed that surgical RD improves LV
function and prevents HF in rats after myocardial
infarction (MI) (17–19). In large animal models of
rapid pacing-induced HF, catheter-based RD also
reduced systemic neurohormonal activation and
renal norepinephrine content, and improved LV
function and dyssynchrony (20–22). Nevertheless, theauthors attest they are in compliance with human studies committe
titutions and Food and Drug Administration guidelines, including patien
it the JACC: Basic to Translational Science author instructions page.
nuscript received December 11, 2016; revised manuscript received Januarlong-term beneﬁcial effects of RD on cardiac
function after conventional pharmacological therapy
for HF have not been addressed in these studies. Here,
we hypothesized that RD reduces the myocardial and
renal norepinephrine discharge and improves LV
function in HF. Accordingly, we investigated the
long-term effect of bilateral catheter-based RD, using a
multipolar electrode catheter, on LV contractile
function and regional norepinephrine release in a
porcine model of mixed cardiomyopathy treated with
angiotensin-converting enzyme (ACE) inhibitor and
beta-blocker.
METHODS
STUDY PROTOCOL. Female farm pigs weighing 35
to 45 kg (age 9 to 12 months) were used for this study.
An animal model of HF induced by myocardial
ischemia and rapid pacing (MI þ HF) was created as
described previously (23,24). In brief, all animals
underwent baseline assessment of LV function
using echocardiographic and invasive hemodynamic
assessments. Acute MI was induced in all animals by
coronary artery embolization to the left circumﬂex
artery, followed by 4 weeks of rapid right ventricular
pacing (150 beats/min) using a VVI pacemaker to
induce HF. After ventricular pacing had ceased
for 24 h, repeat echocardiographic and invasive
hemodynamic assessments were performed. Animals
with impaired left ventricular ejection fraction
(LVEF) <45% were randomized to receive medication
alone (control group, n ¼ 10) or catheter-based
bilateral RD (RD group, n ¼ 10) after invasivees and animal welfare regulations of the authors’
t consent where appropriate. For more information,
y 25, 2017, accepted March 5, 2017.
FIGURE 1 Renal Denervation Procedure and Histological Assessment
(A) Renal angiogram of left renal artery in anteroposterior view before renal denervation (RD). (B) A 5-F quadripolar multiple electrode array
ablation catheter (EnligHTNTM, St. Jude Medical, St. Paul, Minnesota) that consists of an expandable basket with 4 electrodes was used
for RD. (C) An example of acute gross histology after RD to show the placement of lesions inside the renal artery. (D) Percentage area of left
ventricular infarct as measured by histological examination in the control group (n ¼ 10) and RD group (n ¼ 10).
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272hemodynamic studies and were followed for 10
weeks. During this period, all animals with or without
RD were treated with daily oral metoprolol succinate
(25 mg) plus ramipril (2.5 mg).
Serial echocardiographic examinations were
performed at 2, 6, and 10 weeks following RD. At
10 weeks, ﬁnal invasive hemodynamic studies
were performed, and all animals were sacriﬁced for
histological and immunohistochemical assessment.
Electrocardiographic parameters, including resting
heart rate, corrected QT interval, and systolic and
diastolic blood pressure, as well as serum biomarkers,
including angiotensin II, B-type natriuretic peptide
(BNP), and norepinephrine levels, were measured at
baseline, immediately post-MI, and before and after
10 weeks of RD. Moreover, the regional venoarterialgradient of norepinephrine from the myocardium and
kidneys was determined by measuring serum
norepinephrine levels from the femoral arteries and
coronary sinus and from the renal arteries and veins,
respectively (7).
RENAL ANGIOGRAM AND CATHETER-BASED RD
PROTOCOL. The animals were laid in a supine
position following induction of anesthesia. Renal
angiography was performed through a 6-F JR4
guiding catheter (Cordis Corp., Miami, Florida) via a
femoral artery cutdown. Intra-arterial nitroglycerin
(200 ug) was injected into the renal arteries via the
guiding catheter and direct renal angiogram was
performed to guide the RD procedure (Figure 1A). In
both the control and RD group, catheterization was
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273performed to collect blood samples from the femoral
arteries and coronary sinus ostium and then from
the bilateral renal arteries and veins to measure the
myocardial and renal veno-arterial gradient (venous-
arterial levels) of norepinephrine, respectively. In
the RD group, catheter-based RD was performed
using a 5-F quadripolar multiple electrode array
ablation catheter (EnligHTNTM, St. Jude Medical, St.
Paul, Minnesota), which consists of an expandable
basket with 4 electrodes that were used for endo-
vascular delivery of radiofrequency energy into the
renal arteries (Figure 1B). The catheter was connected
to a temperature controlled radiofrequency generator
that automatically controls energy delivery using a
proprietary algorithm based on temperature and
impedance feedback. In each main stem of the renal
artery, 1 min of radiofrequency ablation energy at 4 to
10 W with a temperature limit of 60C was performed
at each electrode. This resulted in a spiral pattern of
individual treatment sites spaced rotationally and
longitudinally along the artery (Figure 1C). After RD,
renal angiogram was repeated, and blood samples
were taken from the bilateral renal arteries and veins
to measure the renal spillover of norepinephrine,
renin, and angiotensin II. After the ﬁnal invasive
cardiac hemodynamic assessment at 10 weeks after
RD, blood samples were taken from the bilateral renal
arteries and veins to measure the renal veno-arterial
gradient of norepinephrine. In the control group,
renal angiogram and blood sampling were performed
without RD.
INVASIVE HEMODYNAMIC ASSESSMENT. Invasive
hemodynamic assessment was performed during
induction of MI and before and 10 weeks after RD to
assess changes in LV function (21,22). In brief, a 7-F
combined catheter-micromanometer (Millar In-
struments, Houston, Texas) was advanced into the
carotid or femoral artery to measure peripheral blood
pressure and then advanced into the LV for measure-
ment of LV pressure, maximum rate of left ventricular
pressure rise (þdP/dtmax), and maximum rate of left
ventricular pressure reduction (dP/dtmax) (23,24).
Moreover, dP/dtmax normalized to instantaneous
developed pressure (IP) (dP/dtmax/IP) was also used to
determine LV contractile function, as the pre-load
condition can be altered during general anesthesia
(25). Pulmonary capillary wedge pressure (PCWP) and
cardiac output were measured with a Swan-Ganz
catheter. Body surface area of each farm pig was
calculated as previously described (26). Stroke volume
index was calculated by the following formula:
stroke volume index ¼ðcardiac outputÞ=
ðheart ratebody surface areaÞECHOCARDIOGRAPHIC MEASUREMENTS. Standard trans-
thoracic echocardiograms including 2-dimensional
and M-mode imaging were performed using a
commercially available echocardiographic system
(Vivid i, GE Vingmed, Horten, Norway) equipped
with a 3-9 MHz transducer. In each animal, standard 2-
dimensional and M-mode echocardiograms were used
to measure the LV volume. To obtain the LV volume
using M-mode echocardiograms, the maximum minor
axis of the LV at end-diastole and -systole were
measured on the parasternal long- or short-axis view,
on the assumption that the LV is a spheroid at the
parasternal long- and short-axis views, to calculate
LVEF (24). All echocardiographic measurements were
interpreted off-line in a blinded fashion by another
independent operator using a computer workstation
(GE Medical, EchoPac, Horten, Norway). The intra-
observer variability of themeasurement of LVEF based
on M-mode measurement was 4% using 20 repeated
random measurements.
BIOMARKERS ASSESSMENT. Serum porcine angio-
tensin II (Peninsula Laboratories, San Carlos, Califor-
nia), BNP (Phoenix Pharmaceuticals, Burlingame,
California), and norepinephrine (Rocky Mountain Di-
agnostics, Boulder, Colorado) levels were measured in
peripheral arterial blood using enzyme-linked immu-
nosorbent assay kits to assess HF status and peripheral
neurohormonal activation. For the measurement of
norepinephrine level, all blood samples were placed in
ice immediately after collection followed by extrac-
tion. Then, all the extracted samples were stored
at 80C, and were measured in a single batch with
calibration using standard control samples. The
coefﬁcients of variation for angiotensin II, BNP, and
norepinephrine were 8.8%, 7.9%, and 11.2%, respec-
tively, based on repeated measurements in 20 random
samples. Femoral arterial and coronary sinus blood
samples and renal arterial and venous blood samples
were also obtained in the control and RD groups
to measure myocardial and kidney norepinephrine
veno-arterial gradients, respectively, at MIþHF status
and at 10-week follow-up. Coronary sinus blood
sampling was performed by using a 6-F JR4 guiding
catheter (Cordis Corp.) positioned at the mid-portion
of the coronary sinus. Moreover, serial measurement
of serum creatinine level was measured as the
assessment of kidney function before and after RD.
HISTOLOGY AND IMMUNOHISTOCHEMICAL ASSESSMENT.
The animals were sacriﬁced at 10-week follow-up
after RD. After euthanasia, the heart was cut into 8
sections (7-to 10-mm thick) perpendicular to the
apical-basal axis. The sections of the LV were traced,
and color photographs of each section were obtained
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274to serve as a permanent record. Planimetry of the
tracings was performed to measure the size of
infarction (as a percentage of the LV mass) (23,24).
Detailed histological and immunohistochemical
assessments of the renal arteries were performed to
determine the degree of denervation after catheter-
based RD. After 10 weeks of RD, and while under
general anesthesia after hemodynamic assessment
and renal angiogram, the pigs’ abdominal aorta and
kidneys were rapidly harvested. The renal arteries
were dehydrated in ascending concentrations of
alcohol and embedded in parafﬁn. Transverse sec-
tions of the renal artery were made every 5 to 8 mm
from its origin up to just distal to the main bifurcation
of the renal artery, resulting in 3 sectioning levels
(proximal, mid, and distal segments). On each level,
5-mm serial sections were cut, and per artery, all
sectioning levels were mounted on a single glass
slide. The sections were immunohistochemically
stained for tyrosine hydroxylase (TH), which are
markers for sympathetic nerve ﬁbers. Endogenous
peroxidase was quenched using 0.03% H2O2 for 30
min, and then the sections were incubated with a
rabbit anti-TH primary antibody (1:1,000 dilution)
(Merck Millipore, Temecula, California) followed by a
horseradish peroxidaseconjugated antirabbit sec-
ondary antibody (1:500 dilution) (DAKO, Glostrup,
Demark) as previously described (27). For ampliﬁca-
tion of the signal, a tyramide signal ampliﬁcation kit
(Perkin Elmer, Waltham, Massachusetts) was applied.
The sections were incubated in the ﬂuorogenic sub-
strate Alexa Fluor 488 tyramide (1:100) (Life Tech-
nologies, Eugene, Oregon) for 10 min and then
coverslipped with mounting medium with DAPI
(Sigma-Aldrich, St. Louis, Missouri). Image analysis
was undertaken using a ﬂuorescent microscope (Leica
DMLB2, Leica, Wetzlar, Germany). The percentage of
TH area staining from each image was quantiﬁed
with Image J software (National Institutes of
Health). For each slide, 5 regions were randomly
selected and examined at 10 magniﬁcation. All
measurements were counted in a blinded fashion.
STATISTICAL ANALYSIS. All data are expressed as
mean  SEM, and analysis was performed using SPSS
software (SPSS Inc., Chicago, Illinois). Comparisons of
parameters between different groups before and after
RDweremade using theMann-WhitneyU test or 1-way
analysis of variance with Tukey’s test, as appropriate.
Serial changes in echocardiographic and invasive LV
hemodynamic parameters and biomarkers at different
time points were compared by 1-way repeated analysis
of variance with Tukey’s test. Statistical signiﬁcance
was deﬁned at a value of p < 0.05.RESULTS
A total of 26 pigs with MI and impaired LVEF docu-
mented on echocardiogram underwent rapid ven-
tricular pacing to induce HF, and 20 animals who
survived after induction of MI þ HF were studied.
These animals were randomized to the control group
(n ¼ 10) and the RD group (n ¼ 10). Histological
examination demonstrated that there were no sig-
niﬁcant differences in the LV infarct size between
the 2 groups (Figure 1D).
ELECTROCARDIOGRAPHIC DATA. There were no
signiﬁcant differences in the resting heart rate
(Figure 2A) and corrected QT interval (Figure 2B) at
baseline, after MI, and during MI þ HF among the
control and the RD groups (all p > 0.05). However, the
resting heart rate was signiﬁcantly lower and
the corrected QT interval was shorter in the RD
group at 10 weeks compared with the control group
(Figures 2A and 2B) (p < 0.05).
HEMODYNAMIC DATA. There were no signiﬁcant
differences in the systolic and diastolic blood pres-
sure (Figure 2C) at baseline, after MI, during MI þ HF,
and at 10 weeks between the control and the RD
groups (all p > 0.05). Similarly, there were no signif-
icant differences in the systolic and diastolic blood
pressure at baseline, after MI, during MI þ HF, and at
10-week follow-up in each group. The PCWP was
signiﬁcantly elevated during MI þ HF compared with
baseline and after MI in both groups. Moreover, in
the RD group, the PCWP was signiﬁcantly lower at 10
weeks compared with during MI þ HF and the control
group at 10 weeks (Figure 2D).
Compared with baseline, LV systolic contractile
function as determined by þdP/dtmax, þdP/dtmax/IP,
and stroke volume index signiﬁcantly decreased after
MI and during MI þ HF in the control and RD groups,
but there were no differences in dP/dtmax (Figures 2E
to 2H). In the control group, there was no change
in þdP/dtmax, dP/dtmax/IP, and stroke volume index at
10 weeks compared with MI þ HF (p > 0.05). Contrary
to this, þdP/dtmax, dP/dtmax/IP, and stroke volume
index signiﬁcantly increased at 10 weeks in the RD
group compared with their MI þ HF status (Figures 2E,
2G, and 2H) (all p < 0.05). Moreover, dP/dtmax/IP and
stroke volume index were also signiﬁcantly higher at
10 weeks in the RD group compared with the control
group (Figures 2G and 2H) (all p < 0.05).
ECHOCARDIOGRAPHIC DATA. After pacing was
turned off for 24 h, echocardiogram showed that
LVEF decreased from 65.3  0.9% at baseline to
38.7  2.1% after induction of MI þ HF (p < 0.001). As
FIGURE 2 Hemodynamic Assessment
Serial changes in (A) resting heart rate; (B) corrected QT interval; (C) systolic and diastolic blood pressure; (D) pulmonary capillary wedge pressure;
(E) þ maximum rate of left ventricular pressure rise (dP/dtmax); (F) dP/dtmax; (G) þdP/dtmax normalized to instantaneous developed pressure (IP)
(dP/dtmax/IP); and (H) stroke volume index at baseline, post myocardial infarction (post-MI), after induction of heart failure (MI þ HF), and at 10-week
follow-up in the control group (n ¼ 10) and renal denervation (RD) group (n ¼ 10).
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FIGURE 3 Echocardiographic and Neurohormonal Parameters
Serial changes in (A) left ventricular (LV) end-diastolic and -systolic diameter; (B) LV ejection fraction; and serum levels of (C) brain natriuretic peptide and
(D) peripheral blood norepinephrine at baseline, post-MI, after MI þ HF, and at 10-week follow-up in the control group (n ¼ 10) and RD group (n ¼ 10). (E) Changes in
the venoarterial gradients of norepinephrine over the myocardium and left and right kidney during MI þ HF and at 10-week follow-up in the control group (n ¼ 10) and
RD group (n ¼ 10). Serial changes in serum levels of (F) angiotensin II and (G) creatinine at baseline, post-MI, after MI þ HF, and at 10-week follow-up in the control
group (n ¼ 10) and RD group (n ¼ 10). Abbreviations as in Figure 2.
Continued on the next page
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276shown in Figure 3A, maximum minor axis of the LV
at end-diastole and -systole during MI þ HF was
signiﬁcantly increased compared with baseline in
both groups. At 10 weeks, the LVDs were smaller
in the RD group compared with the control group
(p < 0.05).
There were no signiﬁcant differences in LVEF at
baseline, after MI, and during MI þ HF between the
control and the RD groups (Figure 3B) (p > 0.05). Se-
rial echocardiogram showed no changes in LVEF at
10 weeks compared with MI þ HF in the control group
(Figure 3A) (p > 0.05). However, LVEF was signiﬁ-
cantly increased at 10 weeks in the RD group
compared with during MI þ HF, and was higher than
the control group at 10 weeks (Figure 3B) (p < 0.05).BIOMARKER DATA. Serial changes in serum BNP
(Figure 3C) and norepinephrine (Figure 3D) in the
control and RD groups showed similar trends: their
levels progressively increased after induction of
MI þ HF compared with baseline (p < 0.05). At 10
weeks, the serum BNP was signiﬁcantly lower
compared with MI þ HF in the RD group (Figure 3C)
(p < 0.05), but not in the control group (p > 0.05).
However, there was no difference in the serum
BNP level between the control and RD groups at
10 weeks. At 10 weeks, the serum norepinephrine
level was still persistently elevated in both groups
compared with their baseline (p < 0.05), and there
was no signiﬁcant difference between the control
and RD group (p > 0.05).
FIGURE 3 Continued
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277Interestingly, the cardiac veno-arterial gradient of
norepinephrine was signiﬁcantly elevated in the
control group at 10 weeks compared with during MI þ
HF (p < 0.05), but not in the RD group (p > 0.05)
(Figure 3E). Moreover, the cardiac veno-arterial
gradient of norepinephrine was signiﬁcantly
elevated in the control group at 10 weeks compared
with the RD group (Figure 3E) (p < 0.05). Both the
right and left kidney veno-arterial gradient of
norepinephrine remained unchanged at 10 weeks
compared with during MI þ HF in the control group
(Figure 3E) (p > 0.05). However, the right and left
kidney veno-arterial gradient of norepinephrine was
lower at 10 weeks compared with during MI þ HF inthe RD group (Figure 3E) (p < 0.05 for right kidney).
Furthermore, the right and left kidney veno-arterial
gradient of norepinephrine was signiﬁcantly lower
in the RD group at 10 weeks compared with the con-
trol group (Figure 3E) (p < 0.05). Taken together,
these ﬁndings show that RD prevents the increasing
myocardial norepinephrine gradient and reduces the
renal norepinephrine gradient in HF.
There were no signiﬁcant changes in serum
angiotensin II (Figure 3F) and creatinine (Figure 3G)
levels at baseline, after MI, during MI þ HF, and at 10
weeks in both groups (all p > 0.05). Moreover, there
were also no signiﬁcant differences in serum angio-
tensin II and creatinine levels at baseline, after MI,
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278during MI þ HF, and at 10 weeks between the control
and the RD groups (Figures 3F and 3G) (all p > 0.05).
HISTOLOGY AND IMMUNOHISTOCHEMICAL DATA.
Histological examination demonstrates that catheter-
based RD denervated the renal sympathetic nerves
around the renal arteries (Figure 4A), and semi-
quantitative examination revealed a similar percent-
age area of TH positive sympathetic nerves at the
proximal, mid, and distal segment of renal arteries in
the control group (Figure 4B). Moreover, in the RD
group, the percentage area of TH-positive sympa-
thetic nerves at the proximal, mid, and distal seg-
ments of renal arteries was signiﬁcantly lower than in
the control group (Figure 4B) (p < 0.05). These results
demonstrate that catheter-based RD signiﬁcantly
denervated the renal sympathetic nerves around
the renal arteries.
DISCUSSION
In this study, we investigated the long-term effects of
bilateral RD using a catheter-based multielectrode
catheter in a porcine model of HF induced by MI and
rapid pacing. Our results showed that the catheter-
based multielectrode catheter can effectively dener-
vate renal sympathetic nerves to prevent elevation of
myocardial norepinephrine gradient, reduce renal
norepinephrine gradient, and improve LV function,
as measured by serial echocardiographic measure-
ment of LVEF and invasive hemodynamic assess-
ments of dP/dtmax/IP and stroke volume index, on
top of conventional pharmacological therapies with
ACE inhibitor and b-blocker in HF. However, there
was no signiﬁcant change in serum angiotensin II and
creatinine level after RD.
Catheter-based RD has emerged as a non-
pharmacological approach for treatment of refractory
hypertension via decreasing sympathetic activities
(6,11–14). In HF, sympathoexcitation is associated
with increased mortality and progression of LV
dysfunction (3,4). As a result, RD has been proposed
as a novel therapy for HF via suppression of sympa-
thetic activities. Prior experimental studies (17–19)
showed that surgical RD can prevent adverse LV
remodeling after MI in rats. In an ovine model of
pacing-induced HF, short-term catheter-based RD
reduced renal norepinephrine content (22). Moreover,
long-term catheter-based RD has also been shown to
reduce serum BNP, angiotensin II, and aldosterone
levels and improve LV function in a canine model of
pacing-induced HF (20,21). Nevertheless, the poten-
tial effect of RD in HF after optimal evidence-based
pharmacological therapies and the extent of RD
after the procedure were not addressed in thesestudies. Moreover, the effect of RD on sympathetic
overactivation in HF remains unclear.
In this study, we conﬁrm that catheter-based
RD can improve LV function in a clinically relevant
large-animal model of MI with HF. Our results
demonstrated that bilateral RD reduced PCWP and
improved LV contractile function, as measured by
echocardiogram and detailed invasive hemodynamic
assessment. Moreover, reverse remodeling of the LV
dimensions, as shown by signiﬁcant reduction of
LV end-systolic and -diastolic diameters after RD
compared with control, were observed. However, a
major concern about the use of RD in HF is the risk
of hypotension and kidney injury after the proced-
ure. In contrast to previous experimental studies
(20–22), we did not observe any signiﬁcant change in
blood pressure or angiotensin II level after RD. This
may be attributed to the concomitant use of ACE
inhibitors in this study, and thus, the effect of RD on
blood pressure via the suppression of the renin-
angiotensin-aldosterone system is masked. Indeed,
recent human pilot studies on RD in HF patients
treated with ACE inhibitors or angiotensin II
blockers also demonstrated no signiﬁcant change in
blood pressure after the procedure (28). However, it
is also possible that the blood pressure response to
RD involves a more complex mechanism in which
the beneﬁcial effects on HF are mediated through
attenuation of adverse neurohormonal feedback
loops, such as regional changes in the norepineph-
rine gradient, as observed in this study. In this
study, the lack of signiﬁcant differences in serum
norepinephrine and angiotensin II between the
control and RD groups might also be related to the
use of ACE inhibitors and beta-blockers, albeit at
relatively low doses. Importantly, we did not
observe any signiﬁcant change in kidney function as
measured by the serum creatinine level after RD.
Therefore, our data provide further reassurance to
support the safety of RD in HF.
One of the important ﬁndings of this study is that
effective bilateral RD, as conﬁrmed by histological
examination, is associated with the prevention of
elevation of myocardial norepinephrine gradient as
observed in the control group, and signiﬁcantly
reduced the renal norepinephrine gradient in HF. In
the control group, treatment with ACE inhibitors and
b-blockers was associated with a reduction in the
peripheral but not coronary sinus and renal norepi-
nephrine levels. These ﬁndings suggest persistent
sympathetic overactivation in the heart and kidney
despite conventional pharmacological therapies
for HF. In contrast, decreased cardiac and renal
norepinephrine gradients were observed after
FIGURE 4 Histological Assessment of Renal Denervation
(A) Representative histological image of the renal sympathetic nerve as determined by tyrosine hydroxylase (TH) staining (red arrows) to show its distribution at the
proximal, mid, and distal segments of renal arteries in the control and renal denervation (RD) groups. (B) Histological examination on the renal sympathetic nerve as
determined by the immunoﬂuorescence staining of TH-positive nerve in the control and RD groups. (Top) The percent area of TH-positive nerve at the proximal, mid,
and distal segments of the renal arteries in the control and RD groups. (Bottom) The representative image of the immunoﬂuorescence staining of TH-positive nerve
(red arrows) at the proximal, mid, and distal segments of the renal arteries in the control and RD groups.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: RD has
been proposed as novel therapy for treatment of HF. In a
preclinical large-animal model of HF, we have demon-
strated that successful bilateral RD using catheter-based
radiofrequency ablation decreased myocardial and renal
norepinephrine gradients and improved LV contractile
function on top of conventional medical therapies with
ACE inhibitor and beta-blocker.
TRANSLATIONAL OUTLOOK: Our ﬁndings provide
further support for future clinical investigation on the
use of catheter-based RD for treatment of HF.
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280bilateral RD. It is possible that elimination of renal
afferent and efferent sympathetic nerves reduces
not only the renal sympathetic activation as shown
in previous studies (22), but also the central sym-
pathetic neural outﬂow to decrease cardiac norepi-
nephrine gradient.
STUDY LIMITATIONS. First, there is a potential effect
of renal nerve reinnervation after RD, as observed in
recent experimental studies (28). Second, the direct
causal relationships between the change in cardiac
and renal norepinephrine gradient and improvement
in LV function remain unclear. Third, the doses of
ACE inhibitors and beta-blockers were low without
titration. Therefore, our results cannot be extrapo-
lated to include patients with truly maximally toler-
ated medical therapies. Final, the renal excretion of
norepinephrine in the urine was not measured in this
study due to the difﬁculty in collecting 24-h urine in
pigs. Therefore, the overall changes in the kidney
norepinephrine levels could not be determined, as a
substantial portion of norepinephrine is excreted
from the kidney.
CONCLUSIONS
Our ﬁndings provide further evidence to support
the application of catheter-based RD for treatmentof HF. Several ongoing clinical studies will assess
the long-term safety and efﬁcacy of catheter-based
RD in HF (15,29).
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